The top three pharmacy benefit managers hiked the prices of dozens of 'specialty' generic drugs, some by more than 1000% of ...
Charles River Laboratories is predicting 2025 to be as tough as last year for CDMOs as pharma customers continue to cut costs ...
Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope.
Nippon Shinyaku pays $110M upfront to Regenxbio for US/Asia rights to RGX-121 and RGX-111 gene therapies for ...
Private investment firm Bridgewest is combing its Australia-based biologics CDMO BioCina and its sterile injectable ...
IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.
XO Health launches health plan in 4 cities, offering employers alternative coverage with fixed-price care packages and ...
Four Lykos Therapeutics board members have stepped down and another departed last month, the aftermath of a stalemate over how to finance the psychedelic company's clinical future.
For as long as I’ve been a healthcare reporter, the JP Morgan Healthcare Conference has served as a newsy way … Get ...
Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative ...
Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...
Moderna is slashing its 2025 revenue estimate by $1 billion and expanding cost-cutting measures as it continues to struggle ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback